Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

Full text not available from this repository.
Item Type: Article
Status: Published
Official URL: https://doi.org/10.1093/annonc%2Fmdz011
Journal or Publication Title: Annals of Oncology
Volume: 30
Number: 4
Page Range: pp. 582-588
Date: 2019
Divisions: Melanoma Oncology and Immunology
Depositing User: General Admin
Identification Number: 10.1093/annonc/mdz011
ISSN: 09237534
Date Deposited: 21 Dec 2020 06:00
Abstract:

Background: Pembrolizumab demonstrated robust antitumor activity and safety in the phase Ib KEYNOTE-001 study (NCT01295827) of advanced melanoma. Five-year outcomes in all patients and treatment-naive patients are reported herein. Patients whose disease progressed following initial response and who received a second course of pembrolizumab were also analyzed.

Patients and methods: Patients aged ≥18 years with previously treated or treatment-naive advanced/metastatic melanoma received pembrolizumab 2 mg/kg every 3 weeks, 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks until disease progression, intolerable toxicity, or patient/investigator decision to withdraw. Kaplan-Meier estimates of overall survival (OS) and progression-free survival (PFS) were calculated. Objective response rate and PFS were based on immune-related response criteria by investigator assessment (data cut-off, September 1, 2017).

Results: KEYNOTE-001 enrolled 655 patients with melanoma; median follow-up was 55 months. Estimated 5-year OS was 34% in all patients and 41% in treatment-naive patients; median OS was 23.8 months (95% CI, 20.2-30.4) and 38.6 months (95% CI, 27.2-not reached), respectively. Estimated 5-year PFS rates were 21% in all patients and 29% in treatment-naive patients; median PFS was 8.3 months (95% CI, 5.8-11.1) and 16.9 months (95% CI, 9.3-35.5), respectively. Median response duration was not reached; 73% of all responses and 82% of treatment-naive responses were ongoing at data cut-off; the longest response was ongoing at 66 months. Four patients [all with prior response of complete response (CR)] whose disease progressed during observation subsequently received second-course pembrolizumab. One patient each achieved CR and partial response (after data cut-off). Treatment-related AEs (TRAEs) occurred in 86% of patients and resulted in study discontinuation in 7.8%; 17% experienced grade 3/4 TRAE.

Conclusions: This 5-year analysis of KEYNOTE-001 represents the longest follow-up for pembrolizumab to date and confirms the durable antitumor activity and tolerability of pembrolizumab in advanced melanoma.

Clinical trial registry: ClinicalTrials.gov, NCT01295827.

Keywords: long-term follow-up; melanoma; metastatic; overall survival; pembrolizumab; treatment-naive.

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology.

Creators:
Creators
Email
Hamid, O.
UNSPECIFIED
Robert, C.
UNSPECIFIED
Daud, A.
UNSPECIFIED
Hodi, F.S.
UNSPECIFIED
Hwu, W.J.
UNSPECIFIED
Kefford, R.
UNSPECIFIED
Wolchok, J.D.
UNSPECIFIED
Hersey, P.
UNSPECIFIED
Joseph, R.
UNSPECIFIED
Weber, J.S.
UNSPECIFIED
Dronca, R.
UNSPECIFIED
Mitchell, T.C.
UNSPECIFIED
Patnaik, A.
UNSPECIFIED
Zarour, H.M.
UNSPECIFIED
Joshua, A.M.
UNSPECIFIED
Zhao, Q.
UNSPECIFIED
Jensen, E.
UNSPECIFIED
Ahsan, S.
UNSPECIFIED
Ibrahim, N.
UNSPECIFIED
Ribas, A.
UNSPECIFIED
Last Modified: 21 Dec 2020 06:00
URI: https://eprints.centenary.org.au/id/eprint/242

Actions (login required)

View Item View Item